TTY Biopharm, a pharmaceutical company, announced its plans to expand the global reach of its microliposome and microsphere-based products, starting with the Lipo-AB shipments to the United States in 2023. This move has contributed to a 9% revenue increase in the first half of the year, reaching NT$2.65 billion (US$83.2 million). The company reported a combined gross profit margin of 60% and earnings per share (EPS) of NT$2.2.
CEO Sara Hou highlighted ongoing efforts to optimize dosage forms and increase production batches. TTY Biopharm is negotiating contracts with European regions, aiming to ship Lipo-AB to additional countries next year. However, challenges remain in the progress of generic drugs, with microsphere-related developments expected to bear fruit by 2026.
In addition to its global expansion efforts, TTY Biopharm is focusing on Southeast Asia, particularly Vietnam, due to its close ties with Taiwan. The company is collaborating with local teams and government policies, with plans to provide diverse cancer treatment options once regulatory approvals are secured.
On the authorized drug front, TTY Biopharm is focusing on Lonsurf for colorectal cancer and TS-1 for breast cancer. Recent approvals for both drugs have bolstered the company’s oncology portfolio. While continuing to introduce new drugs through authorization, Taiwan Toyo is also investing in R&D for in-house drug development, particularly in the areas of liposomes and microspheres.
